Status:

RECRUITING

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Lead Sponsor:

AbbVie

Conditions:

Episodic Migraine

Eligibility:

All Genders

6-17 years

Phase:

PHASE3

Brief Summary

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other sy...

Eligibility Criteria

Inclusion

  • Weight is \>= 20 kg (44 lbs) and \< 135 kg (298 lbs).
  • History of episodic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD) -3 (2018) for at least 6 months.
  • Participant has to have 4 to 14 migraine days and \< 15 headache days in the 28-day baseline period per eDiary.
  • To be eligible for the PK substudy, participants must be 6 to 11 years of age (inclusive), with a history of migraine (consistent with a diagnosis according to the ICHD-3 \[2018\]) and per investigator judgment is appropriate to receive preventive treatment for migraine.

Exclusion

  • History of migraine brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018).
  • Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018).
  • Have a current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018).

Key Trial Info

Start Date :

May 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2028

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT05711394

Start Date

May 1 2023

End Date

May 1 2028

Last Update

February 10 2026

Active Locations (98)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 25 (98 locations)

1

Rehabilitation & Neurological Services /ID# 248517

Huntsville, Alabama, United States, 35805-4046

2

The Center for Clinical Trials - Saraland /ID# 271604

Saraland, Alabama, United States, 36571

3

Preferred Research Partners /ID# 249729

Little Rock, Arkansas, United States, 72211

4

Preferred Research Partners /ID# 270406

Little Rock, Arkansas, United States, 72211

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | DecenTrialz